Improving the Clinical Utility of Platelet Count for Cancer Detection in Primary Care: A Cohort Study in England, Canada, and Australia

Author:

Mounce Luke T. A.1ORCID,Calitri Raff1,Hamilton Willie1ORCID,Rafiq Meena23,Emery Jon D.2,Giannakeas Vasily45,Kotsopoulos Joanne46,Bailey Sarah E. R.1ORCID

Affiliation:

1. University of Exeter Medical School, University of Exeter, Exeter EX1 3DB, UK

2. Department of General Practice and Primary Care, Centre for Cancer Research, University of Melbourne, Grattan Street, Parkville, VIC 3010, Australia

3. Epidemiology of Cancer Healthcare & Outcomes (ECHO) Group, Department of Behavioural Science, Institute of Epidemiology and Health Care (IEHC), UCL, London WC1E 7HB, UK

4. Research and Innovation Institute, Women’s College Hospital, Toronto, ON M5S 1B2, Canada

5. ICES, Toronto, ON M5T 3M6, Canada

6. Department of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada

Abstract

The platelet count, a component of the full blood count, has been identified as a useful diagnostic marker for cancer in primary care. The reference range for the platelet count is 150 to 400 or 450 × 109/L; this range does not account for natural variation in platelet count by age and sex. This study used three primary care cohorts from England, Canada, and Australia. Patients aged 40 years and over with a full blood count were included and stratified by age (in 10-year bands), sex, (male/female), and platelet count group. Cancer incidence within one year of the test date was estimated from linked registry data. In all three countries, there was a clear upwards trend in cancer incidence with increasing platelet count for both sexes and at all age groups. Lung and colorectal were the most common sites. These results have important implications for the international application of this work; analysis of local health datasets will be crucial to determining appropriate thresholds. Appropriate upper thresholds will depend on local populations, healthcare needs, and priorities. Further research is needed to assess the likely impact of new recommendations on the healthcare system, on cancer outcomes, and patient benefit.

Funder

Mr David Walton

NIHR Advanced Fellowship

PRiME-Women’s College Hospital Clinical Catalyst Award

the Ontario Ministry of Health (MOH) and the Ministry of Long-Term Care (MLTC).

Publisher

MDPI AG

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3